Emily Himes, MD
Dermatology · Williamsburg, VANPI 1417272006
Payments from drug & device makers
Across 116 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$481
- Amgen$358
- Sun Pharmaceutical Industries Inc.$263
- AbbVie$257
- Pfizer$172
- UCB, Inc.$169
- plus $843 from 16 others
What the payments were for
- Food & beverage$2,44196%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $481 |
| Amgen | 14 | $358 |
| Sun Pharmaceutical Industries Inc. | 11 | $263 |
| AbbVie | 13 | $257 |
| Pfizer | 11 | $172 |
| UCB, Inc. | 7 | $169 |
| Novartis | 8 | $155 |
| LEO Pharma Inc. | 6 | $153 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| Arcutis Biotherapeutics, Inc. | 3 | $64 |
| Sanofi | 3 | $62 |
| Incyte Corporation | 3 | $57 |
| Almirall LLC | 2 | $48 |
| Organogenesis Inc. | 1 | $46 |
| Dermavant Sciences, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $33 |
| Galderma Laboratories, L.p. | 2 | $27 |
| Boehringer Ingelheim | 1 | $24 |
| Biofrontera Inc. | 1 | $22 |
| Aclaris Therapeutics, Inc. | 1 | $17 |
| Revance Therapeutics, Inc. | 1 | $16 |
| Merck | 1 | $13 |
How this compares
$2,541 in reported general payments places this provider in the 50th percentile of 396 dermatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $87,481 |
| Clobetasol Propionate | 160 | $12,211 |
| Fluorouracil | 101 | $7,018 |
| Metronidazole | 70 | $5,020 |
| Ketoconazole | 116 | $2,543 |
| Nystatin | 106 | $1,915 |
| Imiquimod | 65 | $1,681 |
| Azelaic Acid | 14 | $1,675 |
| Desonide | 22 | $1,456 |
| Clindamycin Phosphate | 39 | $1,112 |
| Halobetasol Propionate | 15 | $832 |
| Econazole Nitrate | 23 | $763 |
| Doxycycline Hyclate | 36 | $746 |
| Doxycycline Monohydrate | 27 | $688 |
| Triamcinolone Acetonide | 89 | $575 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Williamsburg
- David PariserNorfolk$7M
- Jennifer DesimoneFairfax$2.3M
- Naiem IssaVienna$2M
- Saurabh SinghFairfax$1.7M
- Vishal PatelLeesburg$1.1M
- Diego DasilvaVirginia Beach$1.1M
- Carrie CobbLynchburg$859K
- Yvonne KnightRichmond$857K
- David BrayAlexandria$799K
- Cyndi Torosky TommasoVirginia Beach$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.